Continuous Lenalidomide Delivery to Reduce Neutropenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dosing regimens of immunomodulatory imide compounds like lenalidomide, pomalidomide, and thalidomide result in peak and valley pharmacokinetic behavior, leading to toxicities such as neutropenia, and do not effectively maintain therapeutic levels for prolonged periods.
Innovation Solution
A method of continuous delivery of immunomodulatory imide compounds at a predetermined hourly rate for a specified number of days, using formulations such as liquid, solid, semi-solid, or transdermal patches, to achieve steady-state plasma levels and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If standard pulsatile dosing regimen is used, then ease of operation is improved, but toxicities such as neutropenia increase and therapeutic levels are not maintained for prolonged periods
Solution Approach 1:
The patent applies continuous infusion delivery to maintain constant plasma concentrations of immunomodulatory imide compounds, eliminating the peak-valley fluctuations inherent in pulsatile dosing. This continuous delivery method keeps drug levels within the therapeutic window without exceeding toxic thresholds, thereby maintaining efficacy while reducing toxicities such as neutropenia.
Solution Approach 2:
The patent changes the dosing parameter from intermittent pulsatile administration to continuous infusion, fundamentally altering the pharmacokinetic profile. By controlling the infusion rate to match the drug's elimination rate, the system maintains steady-state concentrations that optimize therapeutic effect while minimizing toxic side effects.
2Device complexity
If standard pulsatile dosing regimen is used, then device complexity is reduced, but anti-cancer and anti-inflammatory activity is insufficient due to peak and valley pharmacokinetic behavior
Solution Approach 1:
The continuous infusion system ensures uninterrupted drug delivery, maintaining constant plasma concentrations that reliably produce anti-cancer and anti-inflammatory effects. This eliminates the periodic sub-therapeutic valleys that reduce treatment reliability in pulsatile regimens, while the infusion pump technology provides a manageable level of complexity.
Solution Approach 2:
The system incorporates feedback control mechanisms where drug plasma concentrations are monitored and infusion rates are adjusted accordingly. This feedback loop ensures that therapeutic levels are maintained reliably, adapting to individual patient pharmacokinetics and eliminating the fixed-dose limitations of standard regimens.
Data Source
AI summary
Provided are systems and methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.